Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 5/20 | 0.50 |
| ▸ | TUBB | P07437 | 5/20 | 0.50 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.50 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.50 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.50 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.50 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.50 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.50 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.50 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.50 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.50 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.50 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.50 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.50 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616184 | 0.92 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1615959 | 0.91 | TP53 (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1614507 | 0.90 | TUBB4A (0.48) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1616087 | 0.90 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1615854 | 0.88 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1616289 | 0.88 | TUBB4A (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1616172 | 0.88 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1615922 | 0.87 | TUBB4A (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1615197 | 0.87 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL1615425 | 0.87 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | claimed |
| US-7629376-B2 | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | claimed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | claimed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | claimed |
| EP-1794122-B1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMA INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7923466-B2 | treating in a lengthening of circadian rhythm period with 6-aminomethyl-3-phenylsulfanyl-1H-indole-2-carboxylic acid amide; for treating central nervous system diseases and mood disorders, bipolar disorder and sleep disorders, with an enzyme inhibitor | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7629376-B2 | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | AVENTIS PHARMACEUTICALS INC. (US) | 2008-01-31 | — | — | US | disclosed |
| EP-1794122-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | Aventis Pharmaceuticals, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006023467-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Iϵ | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082340-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK2A3, CSNK1G3, CSNK1G1 | TUBB4A 1551/4885TUBB 932/4885TUBA3C 679/4885 |
| US-20080027124-A1 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I | CSNK1G3, CSNK2A3, CSNK1E | TUBB4A 1991/4885TUBB 1280/4885TUBA3C 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.